Across the study, patients who had tumours that were hormone receptor negative (ER/PR negative) had a pCR rate of 65.5%, compared to 40.0% in those whose tumours were HR positive (Diff = 21.5%; 95% CI: 2.3%–45.3%; p = 0.132). This evidence concerns the gene NR4A1 and neoplasm.